NxStage Stock Receives a Third Buy Rating in a Row
BTIG, Piper Jaffray, and Northland Securities have all assigned Buy ratings to NxStage, which trades as NXTM on the NASDAQ. In the past quarter, more insiders have been buying the stock.
Read the full article » | Posted 04-12-2017
Related Articles
- Nephrologist Dr. Roberto Collazo Shares New Treatments for Kidney Disease and ESKD Posted 12-11-2024
- Ellen Lukens from CMMI Presents on the Kidney Care Choices Model Posted 12-11-2024
- 2025 NKF Survey on Kidney Health Priorities Finds Home Dialysis is a Patient Priority Posted 12-11-2024
- FDA Correction on Baxter MiniCap Extended Life PD Transfer Set Posted 12-11-2024